CONTENTS
· Features
· Faculty
· Scientific Agenda
· Who Should Attend?
· Objectives
· Registration
· General Information
· Hotel
  Accommodations
· Organizer

Dear Colleague:

It is with great pleasure that we invite you to participate in European Perspectives in Urologic Oncology: A Case-Based Congress to Enhance Patient Management. This educational Congress will present the latest information on a variety of treatment topics for the care of renal, prostate, and bladder cancer as well as dynamic case discussions with an expert panel. Our goal is to provide you with vital information to optimize patient care and heighten your awareness of current trends and evolutions.

We are excited to be holding this year’s Congress in Prague, Czech Republic. Prague, the capital of Czech Republic, is filled with bridges, cathedrals, gold-tipped towers, and is a destination you won’t want to miss in June!

We look forward to welcoming you to Prague and sharing this important clinical information with you at this essential Congress!

Sincerely,
Joaquim Bellmunt, MD
Mark S. Soloway, MD
Jan Dvořáček, MD
Tomáš Hanuš, MD, PhD

Ferran Algaba, MD
Universita Autonoma de Barcelona
Barcelona, Spain

Gunnar Aus, MD
Sahlgrens University Hospital
Gotenborg, Sweden

Marko Babjuk, MD
Charles University in Prague
Prague, Czech Republic

Christian Barré, MD
Jules Verne Clinic
Nantes, France

Joaquim Bellmunt, MD
Hospital del Mar
Barcelona, Spain

Xavier Cathelineau, MD
Institut Montsouris
Université René Descartes
Paris, France

Christian G. Chaussy, MD, FRCS, Ed
Klinikum Harlaching
Munich, Germany

Savino M. Di Stasi, MD, PhD
Tor Vergata University
Rome, Italy

Jan Dvořáček, MD
Charles University in Prague
Prague, Czech Republic

Richard Fiala, MD
University Hospital
Olomouc, Czech Republic

Tomáš Hanuš, MD, PhD
Charles University in Prague
Prague, Czech Republic

Milan Hora, MD
University Hospital Plzen
Plzen, Czech Republic

Ladislav Jarolim, MD
Charles University in Prague
Prague, Czech Republic

Jiří Klečka, MD
Urologická klinika FN v Plzni
Plzeó, Czech Republic

Per-Uno Malmström, MD, PhD
University Hospital
Uppsala, Sweden

Michaela Matoušková, MD
Institute of Molecular Genetics
Prague, Czech Republic

Raymond Miralbell, MD
University Hospital of Geneva
Geneva, Switzerland

Juan Morote, MD
Vall d’Hebron Hospital
Barcelona, Spain

Sylvie Negrier, MD, PhD
University of Lyon
Lyon, France

Dalibor Pacik, MD
Masaryk University
Brno, Czech Republic

Lubos Petruzelka, MD, PhD
Charles University in Prague
Prague, Czech Republic

Libor Safarik, MD
Charles University in Prague
Prague, Czech Republic

Fritz Schröder, MD
Erasmus MC
Rotterdam, The Netherlands

Mark S. Soloway, MD
University of Miami School of Medicine
Miami, Florida, United States

Vladmír Študent, MD
Palaky University, Olomouc
Olomouc, Czech Republic

Cezary Szczylik, MD
Military Institute of Health Services
Warsaw, Poland

Fred Witjes, MD, PhD
University of Nijmegen
Nijmegen, The Netherlands

Thursday, 26 June 2008

9:00
Welcome and introduction

Renal cancer
Session I: Diagnosis and surgery
Moderator: Tomáš Hanuš, MD, PhD

9:05
How pathology dictates treatment of renal tumors
Ferran Algaba, MD

9:25
Trends in surgery of kidney tumors: Shift to less invasive and nephron-sparing techniques
Milan Hora, MD

9:45
Laparoscopic partial nephrectomy
Xavier Cathelineau, MD

10:05
Management of renal tumors with vena cava involvement
Tomáš Hanuš, MD, PhD

10:25
Panel discussion

10:35
Coffee break

Session II: Renal cancer cases
Moderator: Mark S. Soloway, MD

11:00
Cases
Panel: Ferran Algaba, MD, Xavier Cathelineau, MD, Richard Fiala, MD, Tomáš Hanuš, MD, PhD, and Milan Hora, MD

• Surgical approaches to renal cell cancer
• The role of nephrectomy in the metastatic setting

11:45
Lunch break

Session III: Systemic therapy
Moderator: Joaquim Bellmunt, MD

13:00
Front-line treatment with targeted therapies
Cezary Szczylik, MD

13:20
DEBATE: Immunotherapy vs. targeted therapies in metastatic disease
Sylvie Negrier, MD, PhD
Speaker Invited

13:40
Management of treatment-refractory metastatic disease
Joaquim Bellmunt, MD

14:00
Panel discussion

Session IV: Renal cancer cases
Moderator: Mark S. Soloway, MD

14:10
Cases
Panel: Joaquim Bellmunt, MD, Sylvie Negrier, MD, and Cezary Szczylik, MD

• Systemic immunotherapy and new agents
• Combination therapies with new targeted agents
  

15:10
Coffee break

Prostate cancer
Session V: Screening, surveillance and prognosis
Moderator: Jan Dvořáček, MD

15:30
What conclusions have we reached with PSA screening?
Fritz Schröder, MD

15:50
Active surveillance: Best criteria, candidates, and triggers for active therapy
Gunnar Aus, MD

16:10
Unusual types of prostate cancer: Key points for the urologist
Ferran Algaba, MD

Session VI: Prostate cancer cases
Moderator: Mark S. Soloway, MD

16:30
Cases
Panel: Ferran Algaba, MD, Gunnar Aus, MD, Jan Dvořáček, MD, and Fritz Schröder, MD

• PSA
• Active surveillance
• PIN and atypia

17:00
Chair summary of day one and take home points

17:05
Adjourn

Friday, 27 June 2008

9:00
Welcome and introduction

Prostate cancer
Session VII: Surgical and minimally invasive approaches
Moderator: Libor Safarik, MD

9:05
Open radical retropubic prostatectomy
Christian Barré, MD

9:25
Technical nuances in laparoscopic prostatectomy for localized disease
Xavier Cathelineau, MD

9:45
Radiotherapy role in primary treatment and for salvage therapy post radical prostatectomy
Raymond Miralbell, MD

10:05
HIFU update
Christian G. Chaussy, MD, FRCS, Ed

10:25
Panel discussion

10:35
Coffee break

Session VIII: Systemic therapy

10:55
Androgen deprivation therapy: Optimal timing and management of side effects
Juan Morote, MD

11:15
Emerging targeted therapies in prostate cancer
Joaquim Bellmunt, MD

11:35
Panel discussion

11:45
Lunch break

Session IX: Prostate cancer cases
Moderator: Mark S. Soloway, MD

13:15
Cases
Panel: Jan Dvořáček, MD, Ladislav Jarolim, MD, Dalibor Pacík, MD, Vladimír Študent, MD
Additional panelists: Christian Barré, MD, Joaquim Bellmunt, MD, Xavier Cathelineau, Christian Chaussy, MD, Raymond Miralbell, MD, Juan Morote, MD, Libor Safarik, MD

• Early Prostate Cancer (EPC) trial: What have we learned?
• Hormone therapy and hormone-refractory prostate cancer
• Use of HIFU and radiotherapy
• Management of erectile dysfunction following prostate cancer therapies

14:45
Coffee break

Bladder cancer

Session X: Prognosis, diagnosis and surgery

15:05
Hexvix as a diagnostic and treatment adjunct for Ta - T1 bladder cancer 
Fred Witjes, MD, PhD

15:25
Overview of current AUA and SIU guidelines
Mark S. Soloway, MD

15:45
Panel discussion

15:55
Chair summary of day two and take home points

16:00
Adjourn

Saturday, 28 June 2008

Bladder cancer

9:00
Welcome and introduction

Session XI: Alternative options

9:05
Enhancing the activity of mitomycin C
Savino M. Di Stasi, MD, PhD

9:25
Alternative options for BCG failure
Marko Babjuk, MD

9:45
Panel discussion

Session XII: TA –T1 bladder cancer cases
Moderator: Mark S. Soloway, MD

9:55     
Cases
Panel: Marko Babjuk, MD, Michaela Matoušková, MD, Savino M. Di Stasi, MD, PhD

• Hexvix as a diagnostic and treatment adjunct
• Prognostic factors and management of high grade T1 bladder cancer
• Optimizing efficacy and managing BCG toxicity
• Transurethral resection and urinary diversion

           
10:55
Coffee break
           
11:15   
Case topics continued:

• Intravesical immunotherapy and chemotherapy
• Systemic chemotherapy: indications and drug choices
• Cystectomy

Panel: Marko Babjuk, MD, Michaela Matoušková, MD, Savino M. Di Stasi, MD, PhD

12:00   
Lunch break

Session XIII: Systemic therapies

13:30   
DEBATE: Timing of chemotherapy for muscle-invasive bladder cancer: Neoadjuvant vs. adjuvant
Per-Uno Malmström, MD (Neoadjuvant)
Mark S. Soloway, MD (Adjuvant)

13:50   
Update on systemic therapies in advanced bladder cancer
Lubos Petruzelka, MD

14:10   
Panel discussion

Session XIV: T2 –T3 and N+ bladder cancer cases
Moderator: Mark S. Soloway, MD

14:20   
Cases
Panel: Marko Babjuk, MD, Ladislav Jarolim, MD, Jiří Klečka, MD,
Additional panelists: Per-Uno Malmström, MD, Lubos Petruzelka, MD

• Optimizing efficacy and managing BCG toxicity
• Intravesical immunotherapy and chemotherapy
• Systemic chemotherapy: indications and drug choices
• Cystectomy
• Transurethral resection and urinary diversion

           
15:55
Chair summary of day three and take home points

16:00
Adjourn

This meeting is intended for urologists, medical oncologists, radiation oncologists, surgeons, and other healthcare providers involved or interested in the management of renal, bladder, and prostate cancer. No specialized knowledge other than a basic familiarity with the principles of oncology is needed to participate in this event.

After successful completion of this course, attendees should be able to:

• Comment on the newest trends in imaging and use of biological markers to improve the diagnosis and prognosis of renal, bladder, and prostate cancers
• Implement state-of-the-art surgical advancements in renal, bladder, and prostate cancers
  
• Evaluate the use of immunotherapy and targeted therapies in metastatic renal carcinoma
  
• Debate the use of PSA screening for the detection of prostate cancer
  
• Compare and contrast systemic therapy regimens for hormone-sensitive and hormone-refractory prostate cancer
  
• Employ the use of targeted therapies in prostate cancer
  
• Improve bladder cancer survival via clinical and pathologic predictors
  
• Discuss therapeutic options to manage BCG toxicity and/or BCG failure in patients with bladder cancer
  
• Review the role of intravesical chemotherapy in bladder cancer and describe the optimal agent, timing, and dose of administration
  
• Discuss updates in systemic therapy for bladder cancer
  

Click here to register for this program

REGISTRATION FEES
Regular . . . . . . . . . . . . . . . . . . €495
If payment received by 17 June 2008

Full/Onsite . . . . . . . . . . . . . . . . €595
If payment received after 17 June 2008

ESMO Members*. . . . . . . . . . . . - €50
*proof of eligibility must accompany registration

To Register:You may register online by 17 June 2008 at www.imedex.com or by calling Imedex at +1 (678) 242 090. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the Congress.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

ESMO members receive an additional € 50.00 off the published registration fees.

Payment: To pre-register, registration and payment must be received no later than 17 June 2008. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the meeting is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add € 50 to each wire transaction to cover bank charges. Include the full name of the attendee and the name of the Congress: 2nd Annual European Perspectives in Urologic Oncology, #318. An attendee is not registered until full payment is received.

Wire to: Bank of America, NA London, 1 Alie Street E1ADE London UK, Swift Code: BOFAGB22, Sort Code: 165050 Beneficiary: Bank of America Domestic Deposit #5687, Account #: 600895687029, Reference: Imedex, Inc. Account # 10726-118, IBAN: GB89 BOFA 1650 5095 6870 29.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, Congress materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than 17 June 2008. The amount of registration fees remitted, minus a € 90 administrative charge, will be refunded after the Congress. Substitutions are accepted with written notification. No refunds will be made if notice is received after 17 June 2008.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this Congress should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

CONFERENCE LOCATION
InterContinental Prague
Namesti Curieovych 43/5
Prague, 110 00
Czech Republic
Tel.: +42 0 296 631 111
Fax: +42 0 224 811 216

The Imedex Registration and Information Desk
will be staffed:

Thursday, 26 June 2008 . . . . 8:00 – 17:15
Friday, 27 June 2008 . . . . . . 8:00 – 16:00
Saturday, 28 June 2008 . . . . .8:00 – 16:45

DISCOUNTED AIRFARES
Contact Congress travel agent, Judi Tarpley, CMP, at Williamsburg Travel, for assistance with your travel needs. Williamsburg Travel can also accommodate pre- and post-Congress extensions.

Tel.: +1 (888) 232 9394 or +1 (770) 261 8613
Email: judit@willtrav.com

Italian Participants: Fargo International Meetings & Conventions SRL has been appointed as the official agency for government authorization for Italian participants. You may contact them directly at:

Fargo International Meetings & Conventions SRL
Via Piattro Maroncelli 44/66, 50137 Firenze, Italy
Tel.: +39 055 600 555
Fax: +39 055 609 078

Important Dates
Regular Registration Deadline . . . . . . . .17 June 2008

Presentation Dates . . . . . . . . . . . . . .26-28 June 2008

InterContinental Prague
Namesti Curieovych 43/5
Prague, 110 00
Czech Republic
Tel.: +42 0 296 631 111
Fax: +42 0 224 811 216
http://events.ichotelsgroup.com/DPRD-7AXCHF/PRGHA/website/

Presiding regally above the hilly banks of the Vltava River, the InterContinental Prague is the landmark choice of Prague hotels, providing a sophisticated setting for all types of travel. Experience “The City of One Hundred Spires” from its premier location - in the heart of the areas most famous sights. Just two blocks from historic Old Town, the hotel is ideally located from which to explore the shops, restaurants, and architectural treasures that give this region its distinctive character. Enjoy majestic skyline and romantic river views - from the recently-renovated rooms or the unique rooftop, gourmet restaurant, Zlata Praha. An enchanting destination unto itself, this exceptional Prague Czech Republic hotel offers luxury and comfort in a premier downtown setting.

For the convenience of attendees, a limited number of rooms have been reserved until 5 June 2008 at a discounted rate of € 249.00 single occupancy, classic room or € 269.00 double occupancy, classic room plus VAT, currently at 9%. This rate is not guaranteed outside the Congress dates or after 5 June 2008 or if the room block is full. The rate includes service charge, city tax and a full American buffet breakfast daily.

To reserve your room please contact the InterContinental Prague reservations department at +42 0 296 631 111 or visit the hotel’s website at http://events.ichotelsgroup.com/DPRD-7AXCHF/PRGHA/website/. To receive the group rate, callers must identify themselves as being with the 2nd Annual European Perspectives in Urologic Oncology: A Case-Based Congress to Enhance Patient Management group. Reservation requests received after 5 June 2008 may not be guaranteed the group rate.

          4325 Alexander Drive
          Alpharetta, GA 30022-3740 USA
          Tel.: +1 (770) 751 7332
          Fax: +1 (770) 751 7334
          Email: meetings@imedex.com
          Web: www.imedex.com